QLSF Biotherapeutics

San Francisco, United States Founded: 2016 • Age: 10 yrs
Develops immuno-oncology therapies targeting cancer via bispecific antibodies and clinical trials.

About QLSF Biotherapeutics

QLSF Biotherapeutics is a company based in San Francisco (United States) founded in 2016 by Hieu Van Tran. It operates as a B2B. QLSF Biotherapeutics offers products and services including QL325 CLEC12A x CD3, QL335 LY6G6D x CD3, QL301 PD-L1 x 4-1BB, QL401 PD-L1 x CD47, and QL325 PD-L1 x IL-15. QLSF Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.

  • Headquarter San Francisco, United States
  • Founders Hieu Van Tran
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Qlsf Biotherapeutics Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of QLSF Biotherapeutics

QLSF Biotherapeutics offers a comprehensive portfolio of products and services, including QL325 CLEC12A x CD3, QL335 LY6G6D x CD3, QL301 PD-L1 x 4-1BB, QL401 PD-L1 x CD47, and QL325 PD-L1 x IL-15. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Bispecific antibody targeting acute myeloid leukemia in clinical trials.

Targets colorectal cancer through T cell engagement.

Activates T cells for treating advanced malignant tumors.

Promotes tumor cell phagocytosis in cancer therapy.

Enhances immune response against tumors in clinical stages.

People of QLSF Biotherapeutics
Headcount 10-50
Employee Profiles 9
Employee Profiles
People
Meihua Luo
Senior Scientist
People
Shihao Chen
Co-Founder
People
Shenda Gu
Associate Director
People
Ling Zhang
Senior Scientist

Unlock access to complete

Funding Insights of QLSF Biotherapeutics

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by QLSF Biotherapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - QLSF Biotherapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Qlsf Biotherapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of QLSF Biotherapeutics

QLSF Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Qlsf Biotherapeutics

Frequently Asked Questions about QLSF Biotherapeutics

When was QLSF Biotherapeutics founded?

QLSF Biotherapeutics was founded in 2016.

Where is QLSF Biotherapeutics located?

QLSF Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

What does QLSF Biotherapeutics do?

QLSF Biotherapeutics is an immuno-oncology startup in South San Francisco, focusing on innovative antibody-based therapeutics for cancer. They use rational design to create modular molecules that target immune systems, including T cell engagers and bispecific antibodies. The company conducts clinical trials and partners with pharmaceutical firms like Qilu Pharmaceutical for development and research support.

Who are the top competitors of QLSF Biotherapeutics?

QLSF Biotherapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does QLSF Biotherapeutics offer?

QLSF Biotherapeutics offers QL325 CLEC12A x CD3, QL335 LY6G6D x CD3, QL301 PD-L1 x 4-1BB, QL401 PD-L1 x CD47, and QL325 PD-L1 x IL-15.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available